Shoulder Innovations to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference
Rhea-AI Summary
Shoulder Innovations (NYSE: SI) said management will present at the Canaccord Genuity 2026 Musculoskeletal Conference on Tuesday, March 3, 2026 at 2:00 p.m. CT / 12:00 p.m. PT.
According to the company, a live webcast and archived replay will be available via the Investor Relations section of its website.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Earnings date notice | Neutral | +12.0% | Announced timing for Q4 and full-year 2025 financial results release. |
| Feb 03 | Conference participation | Neutral | -6.0% | Management participation in BTIG MedTech and related investor meetings. |
| Dec 03 | Strategic partnership | Positive | +0.1% | Partnership to develop shoulder-specific micro-robotic surgical platform. |
| Nov 19 | Conference participation | Neutral | -4.8% | Fireside chat at Piper Sandler healthcare conference for investors. |
| Nov 18 | Product launch | Positive | +2.6% | Full commercial launch of InSet™ 70 humeral stem for shoulder arthroplasty. |
Recent conference participation and product/partnership announcements have generally seen modest price reactions, with larger moves tied to upcoming financial result dates.
Over the last few months, Shoulder Innovations reported an upcoming earnings release on March 10, 2026, announced participation in multiple investor conferences, launched the InSet™ 70 humeral stem, and formed a robotic-platform partnership with Interventional Systems on December 3, 2025. Price reactions ranged from a +12% move on the earnings date announcement to smaller, mixed moves on conference news and incremental gains on product and partnership updates. Today’s conference participation fits this pattern of ongoing investor engagement and commercialization progress.
Market Pulse Summary
This announcement highlights Shoulder Innovations’ continued engagement with the investment community via the Canaccord Genuity Musculoskeletal Conference on March 3, 2026. With the stock previously at $13.06, above its $11.05 200-day MA and ahead of the scheduled March 10, 2026 earnings release, investors may focus on how management frames growth, commercialization of products like the InSet™ 70, and progress on strategic partnerships when assessing the company’s trajectory.
AI-generated analysis. Not financial advice.
A live and archived version of the presentation will be available on the "Investor Relations" section of the Shoulder Innovations website at https://ir.shoulderinnovations.com/.
About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations' ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations' ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.
Contact
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
ir@shoulderinnovations.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shoulder-innovations-to-participate-in-the-canaccord-genuity-2026-musculoskeletal-conference-302691804.html
SOURCE Shoulder Innovations